

When your child has a complex health condition—such as autism or epilepsy—it’s natural to want to explore all possible treatment options to improve their quality of life. Among these, cannabis-based products have gained public attention, spurring many parents to consider discussing this option with their child’s clinician. Yet starting this conversation can feel intimidating or risky, especially given the mixed messages and limited guidance available.

This post aims to guide you on how to **discuss cannabis with your child’s existing care team** in a way that fosters mutual respect and shared decision making, without conflict. We’ll clarify key medical concepts, overview what reputable organizations such as the NICE and the GMC recommend, and highlight important nuances between conditions and evidence levels.

Understand What Symptom or Condition You Are Discussing

A foundational step [medical cannabis for sleep](#) before any discussion is to clearly identify the symptom or condition you are seeking to address with cannabis. This is critical because *autism itself is not a medical disease to be “treated” with cannabis*, but some children with autism may have co-occurring conditions or specific symptoms such as severe epilepsy or behavioral challenges.

Autism vs. Co-occurring Conditions

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by differences in social communication and restricted or repetitive behaviors. It is *not* currently recognized as a condition that cannabis products can treat or cure. However, many children with autism also experience health issues such as:

- Epilepsy
- Sleep disturbances
- Anxiety or mood difficulties
- Challenging behaviors

It is these co-occurring symptoms or diagnoses that parents may hope to target. Knowing exactly which symptom you want to manage helps your child’s clinician assess relevant evidence and advise appropriately.

Key Step: Define the Symptom First, Then the Treatment

- What is the specific symptom or condition you believe cannabis could help?
- Is this symptom already part of your child’s current care plan?
- Have you researched if cannabis has proven effectiveness for this symptom?

By focusing the conversation on symptoms and co-occurring health concerns—not autism broadly—you and your clinician can have a more concrete and constructive discussion.

Know What NICE Guidance Currently Says (and Doesn’t Say)

The National Institute for Health and Care Excellence (NICE) offers independent, evidence-based guidance on health conditions, medications, and treatments used in the UK. Though NICE does not provide specific guidance recommending cannabis for autism or most related conditions, it has stringent guidance on cannabis use in certain circumstances.

Current NICE Recommendations on Cannabis-Based Products

Condition NICE Guidance Status Remarks Dravet Syndrome (a rare epilepsy) Recommended for certain patients Cannabidiol (CBD) approved as adjunct therapy to reduce seizures Lennox-Gastaut Syndrome (rare epilepsy) Recommended for certain patients CBD as adjunct therapy for treatment-resistant seizures Autism Spectrum Disorder Not recommended No evidence supports cannabis use Behavioral or sleep problems in autism Not recommended Insufficient evidence; behavioral interventions preferred

In sum, cannabis-based medicinal products are NICE-approved *only for very narrow epilepsy indications* (Dravet and Lennox-Gastaut syndromes), and even then as an adjunct to other medications. For autism or behavioral symptoms, NICE does not recommend cannabis, citing a lack of robust evidence and safety concerns.

You can search for the most up-to-date guidance yourself in the NICE guidance library.

Know the Limits of Current Evidence and Placebo Effects

Even when cannabis is prescribed licensed for specific epilepsies, it's important to understand:



- Clinical trials have demonstrated reduction in seizure frequency for some people.
- The evidence is not perfect—results can vary between individuals.
- Some positive changes reported informally in non-licensed uses may reflect placebo effects or natural fluctuations.

Therefore, any improvement described as “seems calmer” or “better behavior” without validated measurement tools should be interpreted cautiously.



Why Placebo Effects Matter

The placebo effect occurs when the expectation of benefit leads to perceived or actual improvements. In pediatric conditions with subjective outcomes (e.g., anxiety or sleep), it's especially important to track measurable outcomes carefully.

Clinicians trained following GMC standards will seek treatments backed by objective evidence and will advise accordingly.

How to Approach the Conversation With Your Child's Clinician

Now that you're informed, here are practical steps to help you **discuss cannabis-based treatments with your existing care team** in a respectful and constructive manner:

1. Prepare Before the Appointment

- Write down the specific symptoms you want to address.
- Review current NICE and GMC guidance relevant to those symptoms.
- Gather any credible information or questions you want to raise.

2. Initiate the Discussion Calmly

- Express your wish to understand all possible options, including cannabis, not demand it.
- Ask for the clinician's perspective and reasoning rather than making assumptions.
- Listen carefully, acknowledging the clinician's expertise and concerns.

3. Focus on Shared Decision Making

- Use "we" language: "How can we best address these symptoms together?"
- Request information on benefits, risks, and evidence rather than "approval."
- Discuss how to monitor outcomes with objective measures if any treatment change occurs.

4. Be Open to Alternatives

- Clinicians may suggest behavioral therapies, licensed medications, or referral to specialists.

- Express willingness to explore these options alongside evidence-based treatments.

5. Follow Up and Document

- Ask for summaries of discussions and clinical reasoning for your records.
- Plan regular reviews to assess progress and consider adjustments.

Remember the Legal and Clinical Context

Prescribing cannabis-based products in the UK is tightly regulated. Most clinicians will follow GMC ethical guidance and NICE protocols rigorously. They cannot prescribe cannabis to “treat autism” but may consider licensed cannabis medicines for NHS-approved indications.

Purchasing unlicensed cannabis products on your own carries risks due to unregulated quality and uncertain dosing. Always discuss before starting any new treatment.

Summary Checklist for Talking to Your Child’s Clinician About Cannabis

- **Define the symptom you want to manage, not autism broadly.**
- **Familiarize yourself with NICE guidance and what it permits.**
- **Approach the conversation with curiosity and openness, not conflict.**
- **Seek shared decision making: listen to reasoning and share your views.**
- **Be ready to consider evidence-based alternatives.**
- **Never start cannabis treatments without clinician guidance and monitoring.**

Final Thought

Talking about cannabis with your child’s clinician doesn’t have to be a battleground. With clear symptom definitions, knowledge of current guidelines, and a respectful approach focused on shared decision making, you can be a strong advocate for your child’s health while maintaining a positive partnership with your care team.

For more reliable and up-to-date information, explore resources such as the NICE guidance library and GMC ethical guidance.